Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a clinical-stage pharmaceutical company, announced positive topline results on August 18, 2026 from the Phase 3 LUCIDITY trial of avexitide…
August 18, 2026
August 17, 2026
Femasys Bolsters Its Growth Plan With $30 Million Financing as FemBloc and FemaSeed Programs Advance
Key Points Femasys completed a $30 million private placement after June 30, with up to $60 million in potential additional proceeds if related warrants are…
August 13, 2026
Biomea Fusion Advances Icovamenib Into Obesity as First Patient Is Dosed in Semaglutide Combination Study
Key Points Biomea Fusion dosed the first participant in a new arm of the OPAL platform trial evaluating its oral small molecule icovamenib alongside low-dose…
Key Points Clearmind Medicine Inc. received unanimous approval from an independent Data and Safety Monitoring Board to advance its CMND-100 Phase I/II trial. The decision…
Key Points Annexon added a Month 24 dual-primary endpoint to the ongoing ARCHER II Phase 3 trial of vonapramide in geographic atrophy. The original Month…
Key Points Definium Therapeutics reported positive Phase 3 results for DT120, its investigational LSD-based treatment for generalized anxiety disorder, or GAD. A single DT120 dose…
Ahead of Nuvation Bio’s (NYSE: NUVB) second-quarter results, investors were looking for evidence that the company’s strong first quarter represented the beginning of a sustainable…
Key Points Citius Oncology, Inc. reports accelerating commercial momentum for LYMPHIR, its FDA‑approved treatment for cutaneous T‑cell lymphoma (CTCL). New U.S. institutions ordering LYMPHIR rose…
Key Points BriaCell Therapeutics Corp. received FDA clearance to begin a clinical study of Bria-PROS in prostate cancer. The company is developing Bria-PROS as a…
Key Points Rhythm Pharmaceuticals, Inc. reported preliminary Phase 2 data for RM-718, its investigational MC4R agonist. The early results support continued development of RM-718 in…
July 30, 2026
Cingulate’s Phase 3 CTx‑1301 ADHD Results Published in Leading Child & Adolescent Psychiatry Journal
Key Points Phase 3 pediatric trial results for CTx‑1301 (dexmethylphenidate) in ADHD have been published in a respected child and adolescent psychopharmacology journal, adding peer‑reviewed…
July 30, 2026
Viking Therapeutics (NASDAQ: VKTX): The Next Obesity Catalyst May Be About Staying on Therapy
Key Highlights Phase 3 enrollment for injectable VK2735 is complete, with maintenance dosing data expected later this quarter. Oral Phase 3 development remains on track…